Depression Clinical Trials: How Remote Methods Can Deliver Stronger Evidence
In this webinar, our expert panelists address the challenges and misconceptions associated with depression clinical trials—and discuss the opportunities to leverage remote methods to deliver stronger therapeutic evidence with reduced patient burden. Download the webinar summary and key takeaways in PDF format by filling out the form below.
According to GlobalData’s Clinical Trial Database, Central Nervous System (CNS) studies represent roughly 26 percent of all DCTs conducted since 2015—making CNS the most researched therapeutic area for DCTs. One CNS subcategory in particular is emerging as a prime candidate for the successful deployment of hybrid DCT models: depression.
But, despite the opportunities associated with decentralizing depression clinical trials, many questions remain unanswered:
- How can study teams manage representative recruitment within such a heterogenous patient population?
- How can remote participation be designed to benefit depression patients without jeopardizing data quality?
- How do study teams ensure and monitor participants’ safety while also managing patient fatigue and burden?
- What is the most accurate and ethical way to manage the placebo effect in depression clinical trials?
In this webinar, Taylor Major, MBA MPH, Jenny Ly, PhD, and Faith Matcham, PhD, CPsychol, address these questions and more—drawing from their experiences and expertise in this research space to discuss how remote methods can improve the participant experience and deliver stronger evidence in depression clinical trials.
